This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Subscribe To Our Newsletter & Stay Updated
